{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:40:12Z","timestamp":1789594812964,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40266-015-0264-y","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T12:26:29Z","timestamp":1430742389000},"page":"401-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson\u2019s Disease: A Prospective, Cross-Sectional Study in Non-demented Patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Jes\u00fas","family":"P\u00e9rez-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pagonabarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00fcl","family":"Mart\u00ednez-Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Fern\u00e1ndez-Bobadilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Pascual-Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Gironell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"21 Suppl 4","key":"264_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1\u2013136.","journal-title":"Neurology"},{"issue":"10","key":"264_CR2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","volume":"4","author":"DR Williams","year":"2005","unstructured":"Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson\u2019s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605\u201310.","journal-title":"Lancet Neurol"},{"issue":"11","key":"264_CR3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","volume":"24","author":"AH Evans","year":"2009","unstructured":"Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson\u2019s disease. Mov Disord: Off J Mov Disord Soc. 2009;24(11):1561\u201370.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"1","key":"264_CR4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","volume":"31","author":"AF Leentjens","year":"2009","unstructured":"Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson\u2019s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89\u201398.","journal-title":"Clin Ther"},{"issue":"4","key":"264_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","volume":"10","author":"I Rektorova","year":"2003","unstructured":"Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study. Eur J Neurol: Off J Eur Fed Neurol Soc. 2003;10(4):399\u2013406.","journal-title":"Eur J Neurol: Off J Eur Fed Neurol Soc"},{"issue":"4","key":"264_CR6","first-page":"707","volume":"4","author":"O Kano","year":"2008","unstructured":"Kano O, Ikeda K, Kiyozuka T, Iwamoto K, Ito H, Kawase Y, et al. Beneficial effect of pramipexole for motor function and depression in Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008;4(4):707\u201310.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"264_CR7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380.","journal-title":"Lancet Neurol"},{"issue":"5","key":"264_CR8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601\u20137.","journal-title":"J Neurol"},{"issue":"5","key":"264_CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31815d25ce","volume":"31","author":"I Rektorova","year":"2008","unstructured":"Rektorova I, Balaz M, Svatova J, Zarubova K, Honig I, Dostal V, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol. 2008;31(5):261\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"14","key":"264_CR10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108\u201315.","journal-title":"Neurology"},{"issue":"1","key":"264_CR11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord: Off J Mov Disord Soc. 2011;26(1):90\u20139.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"1\u20132","key":"264_CR12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J Neurol Sci. 2006;248(1\u20132):266\u201370.","journal-title":"J Neurol Sci"},{"issue":"3","key":"264_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1176\/jnp.3.3.243","volume":"3","author":"RS Marin","year":"1991","unstructured":"Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243\u201354 (summer).","journal-title":"J Neuropsychiatry Clin Neurosci."},{"issue":"7","key":"264_CR14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","volume":"19","author":"K Ray Chaudhuri","year":"2013","unstructured":"Ray Chaudhuri K, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofrj M, et al. Rotigotine and specific non-motor symptoms of Parkinson\u2019s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 5","key":"264_CR15","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain: J Neurol. 2013;136(Pt 5):1568\u201377.","journal-title":"Brain: J Neurol"},{"issue":"3","key":"264_CR16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"264_CR17","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-008-0828-8","volume":"35","author":"M Estorch","year":"2008","unstructured":"Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging. 2008;35(9):1636\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"264_CR18","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord: Off J Mov Disord Soc. 2007;22(16):2314\u201324.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"13","key":"264_CR19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/mds.22246","volume":"23","author":"J Kulisevsky","year":"2008","unstructured":"Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A, Trapecio Group S. Prevalence and correlates of neuropsychiatric symptoms in Parkinson\u2019s disease without dementia. Mov Disord: Off J Mov Disord Soc. 2008;23(13):1889\u201396.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"5","key":"264_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"issue":"15","key":"264_CR21","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord: Off J Mov Disord Soc. 2010;25(15):2649\u201353.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"12","key":"264_CR22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314.","journal-title":"Neurology"},{"issue":"1","key":"264_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.2005.083113","volume":"78","author":"D Aarsland","year":"2007","unstructured":"Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson\u2019s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"264_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1099-1166(200102)16:2<184::AID-GPS304>3.0.CO;2-K","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson\u2019s disease with dementia and Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2001;16(2):184\u201391.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"264_CR25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","volume":"80","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"264_CR26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord: Off J Mov Disord Soc. 2009;24(11):1641\u20139.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"15","key":"264_CR27","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","volume":"24","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson\u2019s disease. Mov Disord: Off J Mov Disord Soc. 2009;24(15):2175\u201386.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"3","key":"264_CR28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0891988712455236","volume":"25","author":"LB Zahodne","year":"2012","unstructured":"Zahodne LB, Marsiske M, Okun MS, Bowers D. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):131\u20137.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"6","key":"264_CR29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1017\/S1355617711001068","volume":"17","author":"L Kirsch-Darrow","year":"2011","unstructured":"Kirsch-Darrow L, Marsiske M, Okun MS, Bauer R, Bowers D. Apathy and depression: separate factors in Parkinson\u2019s disease. J Int Neuropsychol Soc: JINS. 2011;17(6):1058\u201366.","journal-title":"J Int Neuropsychol Soc: JINS"},{"issue":"2","key":"264_CR30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mds.24061","volume":"27","author":"SE Starkstein","year":"2012","unstructured":"Starkstein SE. Apathy in Parkinson\u2019s disease: diagnostic and etiological dilemmas. Mov Disord: Off J Mov Disord Soc. 2012;27(2):174\u20138.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"14","key":"264_CR31","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/mds.22229","volume":"23","author":"AF Leentjens","year":"2008","unstructured":"Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Apathy and anhedonia rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord: Off J Mov Disord Soc. 2008;23(14):2004\u201314.","journal-title":"Mov Disord: Off J Mov Disord Soc"},{"issue":"5","key":"264_CR32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1017\/S1355617713000131","volume":"19","author":"S Martinez-Horta","year":"2013","unstructured":"Martinez-Horta S, Pagonabarraga J, Fernandez de Bobadilla R, Garcia-Sanchez C, Kulisevsky J. Apathy in Parkinson\u2019s disease: more than just executive dysfunction. J Int Neuropsychol Soc JINS. 2013;19(5):571\u201382.","journal-title":"J Int Neuropsychol Soc JINS"},{"issue":"2","key":"264_CR33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00415-009-5297-x","volume":"257","author":"KF Pedersen","year":"2010","unstructured":"Pedersen KF, Alves G, Bronnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naive patients with incident Parkinson\u2019s disease: the Norwegian ParkWest study. J Neurol. 2010;257(2):217\u201323.","journal-title":"J Neurol"},{"issue":"2\u20133","key":"264_CR34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(92)90024-X","volume":"215","author":"J Mierau","year":"1992","unstructured":"Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215(2\u20133):161\u201370.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"264_CR35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","volume":"290","author":"J Mierau","year":"1995","unstructured":"Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995;290(1):29\u201336.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"264_CR36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(96)00454-2","volume":"312","author":"MF Piercey","year":"1996","unstructured":"Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312(1):35\u201344.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"264_CR37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(91)90603-Y","volume":"38","author":"RJ Eden","year":"1991","unstructured":"Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav. 1991;38(1):147\u201354.","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"264_CR38","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","volume":"127","author":"MC Coldwell","year":"1999","unstructured":"Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1999;127(7):1696\u2013702.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"264_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1176\/jnp.9.3.471","volume":"9","author":"HS Mayberg","year":"1997","unstructured":"Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci. 1997;9(3):471\u201381 (summer).","journal-title":"J Neuropsychiatry Clin Neurosci."}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0264-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0264-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0264-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:56Z","timestamp":1559504516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0264-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0264-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}